| abstract |
A selective androgen receptor modulator (SARM) compound represented by a structure of formula I: ** (See formula) ** where X is O; G is O; T is OH; R is alkyl, CH2F, CHF2, CF3, CF2CF3, aryl, alkenyl, or OH; R1 is CH3; R2 is H, F, Cl, Br, I, CH3, CF3, OH, CN, NO2, NHCOCH3, NHCOCF3, NHCOR, alkyl, arylalkyl, OR, NH2, NHR, N (R) 2 or SR; R3 is H, F, Cl, Br, I, CN, NO2, COR, COOH, CONHR, CF3 or Sn (R) 3; Z is NO2, CN, COR, COOH, or CONHR; Y is CF3, F, Br, Cl, I, CN, or Sn (R) 3; Q is CN, alkyl, halogen, N (R) 2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH3, NHCSCF3, NHCSR, NHSO2CH3, NHSO2R, OR, COR, OCOR, OSO2R, SO2R or SR; n is an integer from 1-4; and m is an integer from 1-3; for use in treating a subject suffering from RA positive breast cancer, ER positive breast cancer, triple negative breast cancer, advanced breast cancer, refractory breast cancer, metastatic breast cancer or breast cancer that has not responded to treatment with a selective estrogen receptor modulator (tamoxifen, toremifene), aromatase inhibitor (exemestane, anastrozole, letrozole), trastuzumab, adotrastuzumab emtansine, pertuzumab, lapatinib, bevacizumab, and / or fulvestrant. |